New Delhi, May 17 (PTI) Aurobindo Pharma today said it has received approval from the Australian health authority to market Risperidone and Alendronate tablets, used in the treatment of schizophrenia and osteoporosis, respectively, in the Australian market.
The company's subsidiary, Aurobindo Pharma Australia Pty, has received approvals from the Therapeutic Goods Administration (TGA), Australia, for registration of Risperidone tablets in 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, besides oral solution in 1 mg/1 ml strengths, Aurobindo Pharma said in a statement.
In addition, the company has received approval for marketing Alendronate tablets in 70 mg strengths, it added.
According to IMS data, Risperidone products have a market size of nearly USD 27.5 million in Australia, while the market for Alendronate was worth USD 14 million for the twelve months ending September, 2010.